Sanofi adds first vaccine candidate against acne to its R&D pipeline with the take over of an Austrian privately held biotechnology firm

Origimm brings expertise in antigen discovery for immune modulation of skin microbiome-associated disorders Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide Sanofi to leverage its next-generation mRNA platform to unlock … Read the full press release →